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Elucidation of the mechanisms of liver fibrogenesis is important to treat liver fibrosis. In this study, we established rat models 
of liver fibrosis with stages from 0–1, 2, and 3–4 to 4 at 2, 4, 6, and 8 weeks, respectively, by injection of pig serum. Liver fi-
brogenesis was detected by Masson’s trichrome staining. Rat non-parenchymal cells (NPCs) were enriched 4-fold by Percoll 
density gradient centrifugation. Protein extracts from NPCs were prepared at 4 and 8 weeks, separated by two-dimensional 
electrophoresis, and then stained with Coomassie Blue G-250. At 4 weeks, we identified 18 non-redundant differentially ex-
pressed proteins of which protein disulfide-isomerase associated protein 3 (PDIA3) and NDUV showed consistent expression 
at protein and mRNA levels from 4 to 8 weeks. PDIA3 was found to be down-regulated by Western blotting in the rat model 
and immunohistochemically in human liver. Our results revealed important aspects of the pathogenesis/progression of liver fi-
brosis and demonstrated important changes in protein expression levels of NPCs at various stages of liver fibrosis. 
liver fibrosis, proteomics, non-parenchymal cells, protein disulfide-isomerase associated protein 3 
 
Citation:  Zhao QQ, Feng YL, Jia XF, Yin L, Zheng Y, Ouyang DS, Zhou HH, Zhang LJ. Proteome analysis of hepatic non-parenchymal cells of immune liver 




The liver is the largest organ in the body, and liver disease 
has many negative effects on human health. In China, ap-
proximately 600 million people are infected with hepatitis B 
(HBV), of which approximately 130 million are chronic 
carriers of HBV and 30 million are HBV patients. Each year, 
approximately 300000 people do not survive liver disease, 
including liver cirrhosis and primary hepatocellular carci-
noma, and 50% of mortalities are caused by primary hepa-
tocellular carcinoma [1,2]. Most liver disease progresses 
from hepatitis, liver fibrosis and cirrhosis to liver cancer. 
Among these stages, only liver fibrosis can be reversed. 
Liver fibrosis results primarily from the action of hepatic 
stellate cells, non-parenchymal cells (NPCs) of the liver, 
which transdifferentiate into fibrogenic, proliferative, and 
contractile myofibroblasts. NPCs include four main cell 
types, liver sinusoidal endothelial cells (LSECs), lympho-
cytes, Kupffer cells (KCs), and fibrocytes, which play im-
portant roles in mediation of early innate and adaptive im-
mune responses [3–6]. However, there is limited knowledge 
of the proteins and pathways involved in liver fibrosis. Im-
mune liver fibrosis (ILF) models [7–9], which mimic 
chronic hepatic injury caused by HBV, have been widely 
used to study liver fibrosis. Pig serum-induced rat hepatic 
fibrosis [7,8] is the most widely used model because the 
changes characterized by mononuclear cell infiltration and 
fibrotic responses in the periportal area are very similar to 
those in humans [8]. Thus, many researchers have used this 
model [7,10] to study human liver fibrosis, especially that 
caused by HBV [11]. 
Proteomic technologies have high throughput, high sen-
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sitivity, and are widely applied to study liver fibrogenesis 
and cirrhosis development [12–16]. Most proteomic re-
search of liver fibrosis has been performed using tissues, 
plasma, or cell lines. There are few studies of the proteome 
in primary cells, especially NPCs such as KCs [17,18], 
LSECs [19], and hepatic stellate cells [20]. For example, 
Hirsch et al. [18] investigated the effect of ischemia/   
reperfusion injury on the proteome of KCs from a rat model 
of ischemia/reperfusion injury, and found elevation of Cu, 
Zn-superoxide dismutase. Teufelhofer et al. [17] analyzed 
the proteomes of purified rat liver primary cells and blood 
plasma for comparison with that of liver whole tissue. Li et 
al. [19] reported the proteomic profile of the plasma mem-
brane of LSECs from normal rat liver. However, no study 
has reported proteomic changes in the NPCs of a liver fi-
brosis model.  
To increase our understanding of the protein changes in 
fibrotic liver NPCs and identify novel biomarkers to facili-
tate the diagnosis and treatment of liver fibrosis, we applied 
a quantitative proteomic approach to analyze the protein 
expression of NPCs from rat models with various stages of 
liver fibrosis and normal controls. Eight proteins were se-
lected and analyzed by real-time reverse transcription-PCR 
(qRT-PCR). Among these proteins, protein disulfide-  
isomerase associated protein 3 (PDIA3) was analyzed fur-
ther by Western blotting and immunohistochemistry. To our 
knowledge, this is the first proteomic study of NPCs during 
the development of liver fibrosis. 
1  Materials and methods  
1.1  Animal treatments 
A total of 40 eight-week-old male Sprague-Dawley rats 
(180–200 g) were purchased from the Center of Laboratory 
Animals, Shanghai Public Health Clinical Center, Shanghai, 
China. Animal studies were performed following the rele-
vant national legislation and local guidelines. Establishment 
of the animal model was performed at the Center of Labor-
atory Animals according to a previously published proce-
dure [21]. Each rat in pig serum and control groups was 
intraperitoneally injected with 0.5 mL pig serum (COSMO 
BIO, Japan) or 0.5 mL saline, respectively. At 2, 4, 6 and 8 
weeks, five rats from each group were sacrificed following 
starvation for 16–18 h. These rats were designated as ILF-2, 
ILF-4, ILF-6, and ILF-8 for serum-treated rats at 2, 4, 6, and 
8 weeks, respectively, and Nor-2, Nor-4, Nor-6, and Nor-8 
for the respective controls. The rat livers were used for his-
topathology and NPC separation. NPCs from rat livers at 4 
and 8 weeks were used for two-dimensional electrophoresis 
(2DE), qRT-PCR, and Western blot analyses. 
1.2  Hepatic NPC isolation 
NPCs were isolated from liver tissue by collagenase type IV 
(0.05 mg mL1) digestion and density gradient centrifuga-
tion using Percoll (Pharmacia, Sweden) as described else-
where [22,23] with slight modifications. Briefly, liver tis-
sues were perfused for 10 min with pre-perfusion buffer 
followed by collagenase perfusion until digestion. The re-
sulting suspension was filtered through a 200-µm mesh and 
then diluted by 2× the volume with PBS. A sample contain-
ing hepatic parenchymal cells and NPCs was analyzed by 
flow cytometry. The remaining cell suspension was centri-
fuged at 100×g for 5 min at 20°C. The cell pellets were re-
suspended and centrifuged at 400×g for 10 min at 20°C. 
The resulting cell pellet was resuspended in PBS and lay-
ered on top of 25% Percoll. The NPC fraction was enriched 
by density centrifugation using a 25% and 50% Percoll gra-
dient (1:1:1 volume ratio) at 900×g for 30 min at 20°C. 
NPCs between the 25% Percoll layer and upper supernatant 
layer were collected and washed with PBS. After centrifu-
gation at 900×g for 10 min at 20°C, a small sample of the 
NPCs was used to verify the purity by flow cytometry, and 
the remaining NPCs were stored at –80°C until use.  
1.3  Histopathology 
Rat liver tissue was fixed in 4% paraformaldehyde/PBS. 
Five-micrometer paraffin sections were subjected to Mas-
son’s trichrome staining as described previously [21]. He-
patic parenchymal cell and NPC fractions purified by Per-
coll density centrifugation were fixed in 4% paraformalde-
hyde and then stained with Masson’s trichome. 
1.4  Flow cytometric analysis 
NPC purity was evaluated by flow cytometry as described 
previously [24]. Briefly, purified NPCs and total liver cells 
(1×106) were incubated with 1 μL mouse anti-rat CD3-PE, 
anti-CD146-FITC, and anti-F4/80-APC for 30 min at room 
temperature in the dark. After two washes with PBS, the 
cells were resuspended in 3% paraformaldehyde and ana-
lyzed by a BD Diva (BD Biosciences, USA). Unstained 
samples were used as controls. Data analysis was performed 
using FlowJo software.  
1.5  2DE and gel staining  
Pooled NPCs from 4- and 8-week time points were ana-
lyzed by 2DE using an IPGphor isoelectronic focusing sys-
tem (GE Healthcare, USA) and Protein II electrophoresis 
apparatus (Bio-Rad, USA) as described previously [21,25]. 
A total of 1 mg of protein from each sample was applied to 
IPG dry strips (pH 3–10 NL, 180 mm×30 mm×0.5 mm). 
Focusing was performed at 20°C under the following condi- 
tions: 30 V for 12 h, 500 V for 1 h, 1000 V for 1 h, an 8000 V 
gradient for 30 min, and 8000 V for 6 h up to 52.1 kVh. The 
Protein II electrophoresis apparatus was used to run the 
11.5% separation gels. The gels were then stained with 
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Coomassie Blue G-250 as described previously [25].  
1.6  Gel image analysis and statistics 
The 2DE gels were scanned by an Imagescanner (GE 
Healthcare) in transmission mode. Image analysis was con-
ducted with ImageMaster 2D Platinum (GE Healthcare). 
For differential analysis, fibrotic liver samples were com-
pared with healthy control samples at the same number of 
weeks. Each sample was analyzed in at least three replicate 
gels. After spot detection, artifacts were removed by nor-
malizing the individual spot volumes with the total optical 
density (A) values of all spots in the gel. Differential pro-
teomic analysis between the serum-treated and control 
groups was performed using the Student’s t-test in the Im-
ageMaster software. Differences were considered signifi-
cant at P<0.05 and with a threshold of 2-fold changes in 
expression. 
1.7  Identification of differentially expressed proteins 
by mass spectrometry 
After ImageMaster analysis, spots of differentially ex-
pressed proteins were cut out of the gels, digested, and then 
analyzed by nano flow liquid chromatograph (LC)-    
electrospray ionization tandem mass spectrometry (MS) 
according to our previous reports [21,26]. The tryptic pep-
tide mixtures were injected into an Ultimate 3000 instru-
ment (LC Packings, Dionex, USA) with a C18 µ-precolumn 
(300 µm id×5 mm, 5 µm, PepMap™) (LC Packings, Dionex, 
The Netherlands) at a flow rate of 20 µL min1. After de-
salting in the precolumn, the peptides were eluted into a 
C-18 reversed-phase nanocolumn (75 µm id×15 cm length, 
3 µm, PepMap™) (LC Packings) with a continuous acetoni-
trile gradient consisting of 4%–64% solvent B (B: 80% ac-
etonitrile with 0.1% formic acid; A: 0.1% formic acid in 
ddH2O) at a flow rate of 0.3 µL min
1 for 40 min. The elut-
ed peptides were online injected using a PicoTip emitter 
nanospray needle (New Objective, USA) for online ioniza-
tion and peptide fragmentation in an esquire HCT mass 
spectrometer (Bruker-Daltonics, Germany). Chromeleon 
6.80 and EsquireControl 3.2 software were used to control 
the analytical process. 
Mascot 2.2.04 was used for database searches. The 
search parameters were as follows: enzyme, trypsin; allow-
ance for up to one missed cleavage peptide; mass tolerance, 
1.2 Da for MS and 0.6 Da for MS/MS; fixed modification 
parameter, carbamidomethyl (C); variable modification pa-
rameters, oxidation (at Met); auto hits allowed (only signif-
icant hits were reported); results formatted as a peptide 
summary report. Proteins were identified based on peptides 
with ion scores exceeding the threshold (P<0.05), indicating 
identification at a 95% confidence level for matched pep-
tides. Proteins identified by four or more peptides, among 
which at least one peptide had four or more continuous y- or 
b-series ions (e.g., y4, y5, y6, and y7), were accepted with-
out manual checking. The proteins identified with three or 
less peptides were checked manually.  
1.8  Data analysis and bioinformatics 
The function and location of the identified proteins were 
elucidated using the Gene Ontology (GO) database linked to 
SWISS-PROT (www.expasy.org). A protein-protein inter-
action network was drawn by STRING 8.0 (http://string. 
embl.de/) using the identified proteins as search seeds.   
1.9  RNA extraction and qRT-PCR 
Total RNA from NPCs was extracted using Trizol reagent 
(Invitrogen, Life Technologies, USA) following the manu-
facturer’s instructions and those described previously [19]. 
Briefly, qRT-PCR was performed using the iCycler iQ Mul-
ticolor Real-Time PCR Detection System (Bio-Rad) and 
SYBR Green (ToYoBo, Japan). For each qRT-PCR, 2 μL 
cDNA was used with 0.7 μL of 10 nmol L1 sense and anti-
sense primers (Table 1) in a total volume of 25 μL. The 
PCR conditions were 3 min at 95°C, followed by 40 cycles 
of 95°C for 5 s, 60°C for 20 s, and 72°C for 20 s. All reac-
tions were performed in duplicate. The threshold cycle of 
each qRT-PCR was converted to a DNA equivalent by 
reading standard curves generated by amplifying dilutions 
of a linearized plasmid containing 188 bp of GAPDH 
cDNA. The relative quantity of target mRNA was normal-
ized to the mRNA level of the internal control (GAPDH). 
1.10  Western blotting 
Protein extracts (50 μg) of NPCs from rats at 4 and 8 weeks 
were separated by electrophoresis in 11.5% SDS-poly- 
acrylamide gels and then transferred to PVDF mem- 
Table 1  Sense and antisense primers for the eight selected genes 
Gene Strand Primer 
CH60_RAT sense AAAGATGGGGTCACTGTTGC 
 antisense CATCACACCTCTCCGGATTT 
HSP7C_RAT sense CAGAATCCCCAAGATCCAGA 
 antisense GTGACATCCAAGAGCAGCAA 
NDUV2_RAT sense TACACCTTGCATGCTTCGAG 
 antisense TCCTTGGGTGTCAGATCCTC 
OTC_RAT sense CGTCTTCAAGCTTTCCAAGG 
 antisense TTGCAGGCATCAGAACTTTG 
PDIA3_RAT sense TATGATGGGCCTAGGACTGC 
 antisense GATTCAACGTTGGTGTGTGC 
TTHY_RAT sense ATGGTCAAAGTCCTGGATGC 
 antisense GCCAAGAGCCTTCCAGTATG 
UCRI_RAT sense AGGGGAAGAACATGGCTTTT 
 antisense GGGCAATAGTAGCCACCAAA 
ATPB_RAT sense CAGGCTGGCTCAGAGGTATC 
 antisense ATGGGCAAAGGTAGTTGCAG 
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branes (Millipore, USA). The blots were incubated over-
night at 4°C with the following primary antibodies: anti- 
PDIA3 (1:1000; ProteinTech, USA) and rabbit anti-    
prohibitin (1:1000; Abcam, Hong Kong, China). After three 
washes with TBS-Tween, the blots were incubated for 1 h at 
20°C with secondary antibodies. Immune complexes were 
detected by enhanced chemiluminescence and exposure to 
X-ray film.  
1.11  Immunohistochemical analysis of PDIA3 in hu-
man liver tissue 
Immunohistochemistry was performed as described previ-
ously [20]. Briefly, tissue sections were incubated for 1 h at 
room temperature with a rabbit anti-PDIA3 antibody (1:100) 
and then a horseradish peroxidase-conjugated anti-rabbit 
antibody. The signals were detected using a liquid 
3,30-diaminobenzidine staining kit (Gene Tech, USA). Im-
ages were obtained under a BX40 microscope (Olympus, 
Japan) equipped with a logenE PAS9000 at 100× or 400× 
magnification. To semi-quantitatively analyze the expres-
sion of PDIA3 in liver NPCs, each section was randomly 
imaged five times in the domains of NPCs at 400× magni-
fication. PDIA3-positive cells were then counted in each 
image. The ratio of the average number of positive cells 
from 20 patients at stage (S) 3–4 (100 images) to that of 20 
patients at S0–1 (100 images) was considered as the rate of 
PDIA3 expression changes. 
2  Results 
2.1  Histopathological findings 
We established the ILF model according to our previous 
study [21]. As shown in Figure S1 in Supporting Infor-
mation, at 2 weeks after serum injection, inflammatory cell 
infiltration and hepatic fibrosis occurred around the portal 
area, and liver fibrosis was diagnosed as S0–1. At 4 weeks 
post-injection, the liver fibrosis had developed to S2. At 6 
weeks, the rat liver was thin, contained separated and small 
pseudolobules, and was diagnosed as S2, S3, or S3–4. At 8 
weeks, very thick pseudolobules had developed, and the 
diagnosis was S4. In contrast, livers in the control group 
showed no histopathological changes during the experi-
mental period.  
2.2  NPC enrichment 
To analyze the enrichment of NPCs, we performed hema-
toxylin and eosin (H&E) staining and flow cytometric de-
tection of CD146, F4/80, and CD3, which are specific bio- 
markers of LSECs, KCs, and lymphocytes, respectively. In 
the purified NPCs, H&E staining showed that contamina-
tion of red blood cells and hepatocytes was low (Figure 
S2A–D in Supporting Information). As shown in Figure 
S2B in Supporting Information, hepatic parenchymal cells 
were absent. Among the images of H&E staining, we found 
only one liver parenchymal cell. The proportion of red 
blood cells was 11.84% in the purified NPC fraction (Figure 
S2C and D in Supporting Information). These results indi-
cated successful separation of the hepatic NPCs by Percoll 
density gradient centrifugation.  
To quantitatively analyze the enrichment of NPCs, CD3-, 
F4/80-, and CD146-positive cells (representing lymphocytes, 
KCs, and LSECs, respectively) were quantified by flow 
cytometry. Unstained cells were used as controls (Figure S3 
in Supporting Information; Figure 1). In the NPC popula-
tion, CD3-, F4/80-, and CD146-positive cells were 
30.10%±0.20%, 8.04%±0.50%, and 41.17%±0.49%, and 
19.07%±0.35%, 2.52%±0.61, and 11.00%±0.60% in total 
liver cells, respectively. Compared with the total liver cells, 
lymphocytes, KCs, and LSECs were enriched by more than 
1.5-fold (Figure 1A and B), 3.2-fold (Figure 1C and D), and 
3.7-fold (Figure 1E and F) in NPCs, respectively. 
2.3  2-DE and gel image analysis 
Proteins of the ILF models and controls were separated us-
ing pH3-10 NL gel strips in the first dimension and an 
11.5% separation gel in the second dimension. Similar pro-
tein spot profiles were obtained from ILF and corresponding 
control samples. In the ImageMaster analysis, the spot 
numbers of detectable proteins in the Coomassie Blue- 
stained gels were 637±47, 608±43, 639±52, and 602±36 in 
ILF samples at 4 weeks, normal samples at 4 weeks, ILF 
samples at 8 weeks, and normal samples at 8 weeks, respec-
tively. The raw data of the ImageMaster analysis, including 
intensity values, volumes, volume% (after normalization), 
area of identified differential spots, and the numbers of 
matched protein spots, are provided in Table S1 in Sup-
porting Information. The changes at the various time points 
were less than those between the ILF model and controls 
according to the protein spots in 2DE (Figure 2; Figure S4 
in Supporting Information). Based on the average intensity 
ratios of protein spots, a total of 48 protein spots were dy-
namically changed during the development of liver fibrosis 
with 22 and 26 differentially expressed proteins at 4 and 8 
weeks, respectively. Among these proteins, 12 and 14 
up-regulated protein spots were detected at 4 and 8 weeks 
(ILF/normal ratios of 2, P0.05), respectively (data not 
shown). Some of these differentially expressed proteins 
showed consistent regulation, such as spots 1 and 1*, 3 and 
3*, and 14 and 14* (Figure 2; Figure S4 in Supporting In-
formation). Based on the partially magnified images of 
spots 14 and 14* (Figure 3A), significant down-regulation 
was found in all gels from ILF models compared with those 
from the controls at 4 and 8 weeks. However, some proteins 
with inconsistent regulation, such as spots 2, 5 and 8, were 
up-regulated in ILF models at 4 weeks but down-regulated  
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Figure 1  Flow cytometric analysis of CD3-, CD146-, and F4/80-positive cells. NPCs and total liver cells were stained with anti-CD3, -CD146- and -F4/80 
antibodies. Unstained cells were used as the negative control. A and B, C and D, and E and F represent flow cytometry analyses of CD3-, F4/80-, and 
CD146-positive cells among NPCs and total liver cells, respectively. The number of cells in a representative experiment is shown in the panels.  
at 8 weeks (Figure 2C and D, indicated as 2x, 5x, and 8x, 
respectively). Similarly, spot 10, a down-regulated protein 
in ILF models at 4 weeks, was up-regulated in ILF models 
at 8 weeks. To identify the proteins related to liver fibrosis, 
only the differential protein spots in 2DE at 4 weeks were 
recovered and identified by MS. The gels at 8 weeks were 
used to check the dynamic regulation of the differentially 
expressed proteins detected at 4 weeks.  
2.4  Identification of differentially expressed proteins 
Using MS, we identified 18 of the 22 differential protein 
spots with greater than 2-fold expression changes, including 
eight up-regulated and 10 down-regulated proteins in ILF 
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Figure 2  Protein expression profiles of ILF models and normal controls. ILF, immune liver fibrosis; Nor, normal control. Samples from serum- or sa-
line-treated rats at 4 and 8 weeks are represented by 4W and 8W, respectively. Up-regulated proteins are labeled in the ILF gel (A), and down-regulated 
proteins are marked in the normal gel (B). Proteins with consistent mRNA and protein levels continually up- or down-regulated in samples from 4 to 8 weeks 
(C and D) are marked with 1*, 3*, and 14*. The proteins with consistent mRNA and protein levels but opposing expression in samples at 4 and 8 weeks are 
labeled with 10#. Proteins with inconsistent mRNA and protein levels are indicated by 2x, 5x, and 8x. 
models compared with those in normal controls at 4 weeks 
(Table 2). Among these 18 proteins, only one was identified 
by one peptide with a Mascot score of 47 (Table S2, Figure 
S5 in Supporting Information). Each protein had at least one 
peptide with continuous four y or b ions by manual check-
ing. For example, in protein disulfide-isomerase A3 (spot 
14), 40% of the amino acids were accurately detected by 
MS with 22 matched non-redundant peptides (Figure 3B, 
underlines). Based on the representative MS/MS spectra of 
peptide DLLTAYYDVDYEK, almost all b or y ions were 
detected by MS for disulfide-isomerase A3 (Figure 3C). 
The abundance of these differentially expressed proteins 
was low according to the data from exponentially modified 
protein abundance index protein (emPAI) analysis, includ-
ing 14 with an emPAI of <1.0 (Table 2; Table S2 in Sup-
porting Information).  
2.5  Bioinformatic analysis of differentially expressed 
proteins  
To determine the location and function of these proteins, we 
used the UniProt knowledgebase (Swiss-Prot/TrEMBL) and 
GO database. The differentially expressed proteins were 
widely distributed in all types of subcellular organelles, 
including seven in mitochondria, three in the plasma mem-
brane, three in the cytoplasm, three in the endoplasmic re-
ticulum (ER), and others (Table 2). These proteins have 
important functions such as binding (including ATP, DNA, 
and actin binding) (50%), enzymatic activity (38%), elec-
tron carriers (8%), and others (Table 2).  
NPCs perform important functions in liver fibrosis. The 
proteins in NPCs interact with each other and also com-
municate with other hepatic cells. Thus, in this study, a pro-
tein-protein interaction network was created to determine 
the interactions of these differentially expressed proteins 
with each other. For 10 proteins, interactions were detected 
with other proteins, but for seven proteins, no interactions 
were detected in this analysis (Figure S6 in Supporting In-
formation). These interactive proteins included Uqcrfs1, 
Ndufv2, and ATP5B, which interact with each other. In 
addition, Hspa8 interacts with CH60, CH60 with Pdia3, Ttr 
with Alb, and Aldh2 with Otc. Some of these interactive 
proteins had a consistent trend of protein expression, such 
as Ndufv2, ATP5B and Uqcrfs1, which were up-regulated 
in the ILF model, but others showed an opposing expression 
trend, such as PDIA3 and its protein partner CH60, which 
were down- and up-regulated, respectively. Among these 
differentially expressed proteins, HSP7C, NDUV, PDIA3, 
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Figure 3  Representative enlarged 2DE gels and MS/MS protein identification results. A, Partially enlarged gel profiles for spot 14. B, Sequence coverage 
of spot 14. Underlined peptides were detected by MS. C, Representative MS/MS spectrum of peptide DGEEAGAYDGPR from spot 14.  
OTC, UCRI, TTHY, ATPB, and CH60 were located in 
nodes of the network and were thus chosen for qRT-PCR 
analysis.  
2.6  Transcriptional profiles of differentially expressed 
proteins 
To determine whether the protein expression changes occur 
at transcriptional or translational levels, the transcriptional 
alterations of eight selected genes in NPCs from ILF and 
control rats were measured by qRT-PCR (Figure S7 in 
Supporting Information). Among them, five genes showed 
mostly consistent expression at protein and mRNA levels, 
including PDIA3, TTHY, NDUV, ATPD, and CH60. 
PDIA3 and TTHY expression was down-regulated at 4 and 
8 weeks compared with that in the corresponding controls, 
and the degree of down-regulation decreased from 4 to 8 
weeks (Tables 3, Figure 4; Table S3 in Supporting Infor-
mation). mRNAs of NDVU, ATPB, and CH60 were 
up-regulated at both 4 and 8 weeks compared with those in 
the corresponding controls. Among these five differentially 
expressed genes, only PDIA3 and NDUV showed com-
pletely consistent expression at protein and mRNA levels 
from 4 to 8 weeks. 
310 Zhao QQ, et al.   Sci China Life Sci   March (2014) Vol.57 No.3 
Table 2  Differential protein spots in 2DE from ILF models and normal controls at 4 weeks 
Spota) No.b) Protein Scorec) pId) MWe) Cov.f) Regg) emPAI Locationh) Functioni) Interactionj) 
1 ATPB 
ATP synthase subunit beta, 
mitochondrial 





























Cytochrome b-c1 complex 
subunit Rieske, mitochon-
drial 






Complement component 1 
Q subcomponent-binding 
protein, mitochondrial 




1065 6.63 56975 42% 2.30 2.15 Mit. enzyme Aldh2 
8 CH60 
60-kDa heat shock protein, 
mitochondrial 







273 4.66 28550 13% 0.40 0.3 Cyt. binding Tpm4 
10 HSP7C Heat shock cognate 208 5.37 71059 13% 0.49 0.32 Cyt. stress response Hspa8 
11 GUAD Guanine deaminase 171 5.56 51564 14% 0.41 0.22 Unknown enzyme Gda 
12 ANXA3 Annexin A3 235 5.96 36573 21% 0.44 0.59 PM binding Anxa3 















16 ALBU Serum albumin 608 6.09 70716 28% 0.24 1.71 PM/EXP binding Alb 
17 TTHY Transthyretin 209 5.77 15826 30% 0.36 0.83 EXP. binding Ttr 
18 CES3 Carboxylesterase 3 47 6.1 62398 1% 0.07 0.05 ER enzyme Ces3 
a) Spot No. is a unique number that refers to the labels in Figure 2. b) No., accession numbers obtained from the SWISS-PROT database. c) Mascot score. 
d) Theoretical isoelectric point (pI). e) Molecular weight predicted from database. f) Sequence coverage (%) indicates the number of amino acids spanned by 
the assigned peptides divided by the sequence length. g) Protein expression change in ILF models compared with that in normal controls. h) Protein location 
from the GO database. Mit, mitochondrial; Cyt, cytoplasm; PM, plasma membrane (including cytoskeleton, basement membrane, and integral to the mem-
brane); ER, endoplasmic reticulum; EXP, extracellular space; Unknown, no subcellular location information was provided by the GO database. i) Protein 
function from the GO database. j) Abbreviation of differential proteins shown in the protein-protein interaction network.  










14 PDIA3 0.30 0.49 0.01 0.32 
17 TTHY 0.34 Not detectedc) 0.015 0.185 
3 NDUV 4.4 2.91 2.15 1.365 
1 ATPB 8.05 14.6 1.345 2.91 
8 CH60 6.37 No changed) 2.015 2.555 
10 HSP7C 0.40 2.23 0.13 3.47 
2 OTC 2.0 0.29 0.025 1.21 
5 UCRI 4.76 0.63 0.005 1.9 
a) 4W and 8W indicate rats at 4 and 8 weeks, respectively. The values are the ratios of protein expression in ILF rats compared with that in normal con-
trols. b) Values are the ratios of mRNA expression in ILF rats compared with that in normal controls. c) Spot 17, not detected in gels for samples at 8 weeks. 
d) Spot 8, no change was detected in samples at 8 weeks.  
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Figure 4  mRNA expression of eight genes selected from 18 differentially expressed proteins (P<0.05). TTHY-4 and TTHY-8 represent the ratio of se-
rum-treated to saline-treated groups at 4 and 8 weeks, respectively. GAPDH was used as an internal control. For the normal control, the value was set as “1” 
and marked with a line. 
2.7  Verification of PDIA3 expression by Western blotting   
The dynamic changes of one differentially expressed pro-
tein, PDIA3, were validated by Western blot analyses of 
NPCs from the rat ILF model. As shown in Figure 5, 
PDIA3 expression was significantly decreased at 4 and 8 
weeks in the NPCs of serum-treated rats compared with that 
in the controls (Figure 5C), which was consistent with the 
results from 2DE analyses. Furthermore, the samples used 
for Western blotting were checked for consistent protein 
loading by the reference protein (prohibitin) (Figure 5B) 
and Coomassie blue staining (Figure 5A).  
2.8  Immunohistochemical analysis of PDIA3 in human 
liver  
To verify the findings in the rat model, we performed im- 
 
 
Figure 5  Western blot analysis of PDIA3. A, SDS-polyacrylamide elec-
trophoresis. B, Expression of PDIA3 and prohibitin in rat ILF models at 4 
and 8 weeks. C, Signal intensities of specific bands. The y-axis shows the A 
of protein expression. Data are presented as the means and standard devia-
tion (n=3). P<0.05, Student’s t-test. Nor-4, ILF-4, Nor-8, and ILF-8 repre-
sent hepatic protein extracts of NPCs from saline- and serum-treated 
groups at 4 and 8 weeks, respectively. 
munohistochemical analysis of human liver biopsies at 
S0–1 and S3–4 using an anti-PDIA3 antibody. We found a 
high correlation between the immunohistochemical staining 
and proteome expression profiles obtained by 2-DE. In 
S0–1 samples, the positive signals (Figure 6A and B) were 
stronger than those in S3–4 samples (Figure 6C and D). 
Statistical analysis showed that the expression of PDIA3 
was decreased by 2-fold at S3–4 (n=20×5) compared with 
that at S0–1 (n=20×5) (Figure 6E). 
 
 
Figure 6  Immunohistochemical analysis of PDIA3. A–D, Human liver 
tissues at S0–1 (100×) (A), S0–1 (400×) (B), S3–4 (100×) (C), and S3–4 
(400×) (D). E, Statistical analysis of average PDIA3-positive NPC counts 
in each image. Twenty liver tissue samples from patients at S0–1 and 20 
samples at S3–4 were analyzed immunohistochemically. Each section was 
randomly imaged five times at 400× magnification in the domains of NPCs. 
P=0.04, S0–1 (n=100), S3–4 (n=100). 
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3  Discussion 
Rats develop liver fibrosis by treatment with pig serum and 
are thus widely used as a model to study ILF [7,8]. In this 
study, liver tissues from ILF rat models at 2, 4, 6, and 8 
weeks showed ILF at S0–1, S2, S2–4, and S4, respectively. 
At 6 weeks, it is unknown why some rats showed ILF char-
acters of 4 or 8 weeks. Furthermore, S2 and S4 clinically 
represent serious liver fibrosis (liver cirrhosis with ascites). 
Therefore, to detect proteins related to liver fibrosis devel-
opment, liver tissues at S2 and S4 were selected for 2DE 
analysis.  
In this study, we analyzed NPCs from liver tissue. Usu-
ally, researches focus on hepatocytes because of their high 
numbers and important functions in the liver. However, 
NPCs also have very important functions such as immune 
and mediation functions in the liver [36]. The mechanisms 
regulating the responses of NPCs in liver fibrosis are un-
clear. Moreover, differentially expressed proteins might 
play critical roles in the functional changes of NPCs during 
the progression of liver fibrosis, and may be important to 
understand such mechanisms. In addition, proteomic profil-
ing of NPCs can identify biomarkers that may serve as di-
agnostic and prognostic indicators as well as drug targets 
for liver diseases. However, in the liver, the number of 
NPCs is much less than that of hepatic parenchymal cells. 
Thus, identification of proteins in NPCs, especially those 
with low abundance, is difficult in proteomic analyses of 
whole tissues.  
To overcome this problem and identify proteins related 
to liver fibrogenesis in NPCs, we purified NPCs using Per-
coll density gradient centrifugation. As shown by H&E 
staining, lymphocytes, LSECs, and KCs were mainly en-
riched in the NPC fraction. To characterize the enrichment 
of NPCs, CD3-, CD146-, and F4/80-positive cells were an-
alyzed to identify lymphocytes, LSECs and KCs, respec-
tively. Liver parenchymal cells do not express CD3, CD146, 
or F4/80 [27,28]. Although we detected enrichment of CD3-, 
CD146-, and F4/80-positive cells, we did not identify all of 
the NPCs. To our knowledge, it is very challenging and 
unnecessary to characterize all NPCs using biomarkers be-
cause we purified NPCs using the same method for both the 
ILF model and control at 4 and 8 weeks. Furthermore, pro-
teins in a small number of cells might not be detected by 
proteomic approaches.  
In this study, the proteome profiles of NPCs from rat liv-
ers were obtained by 2D gels stained with Coomassie Blue. 
Approximately 700 protein spots were separated, and 18 
differentially expressed proteins were identified by MS.  
To determine the concentrations of the differentially ex-
pressed proteins, we used a MS-based approach known as 
emPAI. This technique reveals the protein concentrations 
based on the correlation between the number of identified 
peptides and the protein abundance in MS-based proteomic 
experiments [29,30]. Here, the emPAI data were obtained 
from protein identification results that were acquired by 
Mascot database search engines. Among the differentially 
expressed proteins, 14 had an emPAI of <0.98, which are 
related to ornithine carbamoyltransferase with concentra-
tions of 8–20 µg L1 in human plasma. Thus, most of the 
differentially expressed proteins have medium or low 
abundance in liver tissue.  
Liver fibrogenesis is progressive and involves the regula-
tion of many proteins. Some proteins may be continuously 
up- or down-regulated, while others may have different reg-
ulatory patterns during fibrogenesis. To dynamically ob-
serve the protein profiles during liver fibrogenesis, proteins 
from the liver at S2 (4 weeks) and S4 (8 weeks) were sepa-
rated by 2DE. As a result, we identified 18 differentially 
expressed proteins.  
Functional analyses revealed that these 18 differentially 
expressed proteins were mainly involved in binding to actin, 
ATP, or DNA, or enzymatic activity. These observations 
may be because of the natural characteristics of proteins that 
bind to other proteins, catalyze biochemical reactions, and 
metabolize all types of materials. A subcellular location 
analysis revealed that seven of the 18 proteins are located in 
mitochondria, including ATPB, OTC, NDUV2, ECH1, 
C1QBP, ALDH2, and CH60. This phenomenon of mostly 
regulated mitochondrial proteins is consistent with the the-
ory that mitochondrial dysfunction acts as a common path-
ogenic mechanism in chronic liver diseases. Dysfunctional 
and/or uncoupled mitochondria enhance the susceptibility of 
hepatocytes to cell death by necrosis via ATP depletion or 
apoptosis via membrane permeabilization [31]. To further 
study the pathways regulated during this process, we con-
structed a protein-protein interaction network. Of the 18 
differentially expressed proteins, seven proteins did not in-
teract with the others. This result is mainly because of two 
reasons: only NPCs were analyzed in this study, and only 
proteins with high abundance can be detected by proteomic 
approaches. 
In this study, mRNA analysis of eight differentially ex-
pressed proteins revealed that five of the eight genes were 
consistently up- or down-regulated from S2 to S4 with 
ATPB, NDUV2, and CH60 showing up-regulation and 
PDIA3 and TTHY showing down-regulation. ATPB, 
NDUV2, and PDIA3 were consistently regulated from S2 to 
S4 at mRNA and protein levels.  
PDIA3 was verified to be down-regulated in the rat ILF 
model at S4 compared with that at S2 by Western blot anal-
yses. Consistent down-regulation was detected in human 
liver tissue at S3–4 compared with that at S0–1. Similar 
results were obtained in a report by Aroor et al., in which 
the protein levels of the basic form of PDIA3 were signifi-
cantly decreased after a chronic ethanol binge [32]. PDIA3 
catalyzes the rearrangement of S-S bonds in proteins and 
has very important functions such as electron carrier and 
cysteine-type endopeptidase activities. Our results might 
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complement or support the theory that mitochondrial dys-
function, especially in the respiratory chain, can induce liver 
fibrosis [33]. Furthermore, PDIA3 might serve as a new 
target to treat liver fibrosis [34]. 
In conclusion, our proteomic analyses of NPCs in fibrotic 
livers and normal controls by 2DE-MS identified a number 
of proteins related to liver fibrosis. We identified three 
genes (PDIA3, ATPB, and NDUV2) with consistent mRNA 
and protein regulation from S2 to S4. PDIA3 was verified 
as down-regulated in liver fibrosis at S4 compared with that 
at S2 by western blot analysis of the rat ILF model at 4 and 
8 weeks and immunohistochemically in human liver at S0–1 
to S3–4. We anticipate that further study of PDIA3 will 
expand our understanding of the mechanisms of liver fibro-
genesis and assist in the development of new therapeutic 
approaches against liver fibrosis.  
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Supporting Information 
Figure S1  Histopathology of liver fibrosis examined by Masson’s trichrome staining. (A–D, 100×) Nor, saline-treated rats livers at 2, 4, 6, and 8 weeks 
(W); ILF, (E–H, 100×), pig serum-treated rat livers at 2, 4, 6, and 8 W. No obvious difference was found at 2–8 W in normal rats. In the ILF model, the 
degree of liver fibrosis was increased gradually from S0–1 at 2 W, S2 at 4 W, and S3–4 at 6 W to S4 at 8 W as highlighted in green and indicated by arrow-
heads.  
Figure S2  H&E staining to monitor the purity of isolated hepatic NPCs. A, H&E staining of the hepatic parenchymal cell fraction, 100×. B, H&E staining 
of the NPC fraction purified by Percoll density gradient centrifugation, 100×. C and D, H&E staining of the NPC fraction, 400×. 1, hepatocytes; 2, NPCs 
(lymphocytes); 3, NPCs (fibrocytes); 4, NPCs (KCs); 5, red blood cells.  
Figure S3  Validation of the enrichment of NPCs by flow cytometry. F4/80, CD146, and CD3 were used to detect LSECs, KCs, and lymphocytes, respec-
tively. CD3-positive cells accounted for 30.3% of NPCs and 18.7% of total liver cells (B and D). F4/80-positive cells accounted for 8.24% of NPCs and 
2.28% of total liver cells (F and H). CD146-positive cells accounted for 42.4% of NPCs and 10.4% of total liver cells (J and L). Unstained cells were used as 
negative controls as shown in A and C for CD3, E and G for F4/80, and I and K for CD146. 
Figure S4  Protein expression profiles of the ILF model and normal control. Twelve raw 2DE gel images labeled with differential spots are shown. ILF, 
immune liver fibrosis; Nor, normal control. Up-regulated proteins are labeled in ILF gels and down-regulated proteins are labeled in Nor gels. 
Figure S5  MS/MS spectrum of the protein (carboxylesterase 3) identified by one peptide. 
Figure S6  Protein-protein interaction network identified by STRING software using differentially expressed proteins as seeds. 
Figure S7  qRT-PCR analysis of the eight selected genes in controls at 8 weeks. GAPDH was used as an internal standard. A, qRT-PCR amplification 
curve. B, Ct values (threshold cycle). C, Standard curve. D, Melting curve. The eight target genes could be amplified and quantified by qRT-PCR. There was 
no detection of non-specific PCR products. 
Table S1  Raw data of ImageMaster software analysis. Intensity value, volumes, volume% (after normalization), area of identified differential spots, and 
the numbers of matched protein spots in each gel are shown 
Table S2  The peptides of differentially expressed proteins 
Table S3  The relative mRNA expression in ILF models compared with that in normal controls at 4 and 8 weeks as determined by qRT-PCR 
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